Professor Angus Dalgleish trained at University College Hospital. He trained in internal medicine and oncology at hospitals in Brisbane and Sydney. He returned to the U.K. in 1984 and undertook a thesis on retroviruses with Robert Weiss. He was appointed as Senior Clinical Scientist at the MRC Clinical Research Centre, Northwick Park where he pursued his interests in HIV pathogenesis and the potential of Thalidomide to treat chronic disease. His suggestion that analogues of Thalidomide could lead to enhancement of the therapeutic activity and reduction of the side effects led to the licensing of Revlimid (Lenalidomide) and Pomalidomide (Pomalyst) for myeloma and lymphoma by Celgene. He was awarded the Joshua Lederberg prize in 2011 in recognition of this work.
Since 1991 he has been Professor of Oncology at St. George’s University of London. During this time he has focussed on the immunotherapy of cancer and has conducted numerous clinical trials involving a variety of vaccines and immunotherapy. Since 2001 he has been the Principal of the Institute for Cancer Vaccines and Immunotherapy. His research team’s work is directly informed by Professor Dalgleish’s work in his clinics.